1. Home
  2. AVPT vs SNDX Comparison

AVPT vs SNDX Comparison

Compare AVPT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AvePoint Inc.

AVPT

AvePoint Inc.

N/A

Current Price

$13.43

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$20.56

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVPT
SNDX
Founded
2001
2005
Country
United States
United States
Employees
3443
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
AVPT
SNDX
Price
$13.43
$20.56
Analyst Decision
Buy
Strong Buy
Analyst Count
12
13
Target Price
$16.64
$38.69
AVG Volume (30 Days)
1.6M
1.1M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$25.00
$107.19
Revenue Next Year
$19.63
$41.88
P/E Ratio
$1,348.94
N/A
Revenue Growth
N/A
627.84
52 Week Low
$8.84
$13.00
52 Week High
$16.77
$25.59

Technical Indicators

Market Signals
Indicator
AVPT
SNDX
Relative Strength Index (RSI) 54.88 54.42
Support Level $12.92 $19.20
Resistance Level $13.71 $20.88
Average True Range (ATR) 0.41 0.75
MACD -0.03 0.14
Stochastic Oscillator 49.84 83.00

Price Performance

Historical Comparison
AVPT
SNDX

About AVPT AvePoint Inc.

AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: